Furuzon Tablets 150 mg (Fluconazole)

Adult dose

The route of administration should be determined according to the patient's clinical condition. Oral formulations are rapidly and almost completely absorbed; therefore, the doses of oral formulations (tablets, capsules, dry syrup) and injectable formulations are the same. 1. Vaginal candidiasis: Administer a single oral dose of fluconazole 150 mg. 2. Systemic candidiasis, including candidemia, disseminated candidiasis, and other invasive Candida infections (peritoneal, endocardial, pulmonary, urinary tract, etc.): The usual dose of this drug is 400 mg once on the first day, followed by 200 mg once daily starting the next day. The dose may be increased to 400 mg once daily according to the patient's response. The duration of treatment should be determined based on clinical response and medical judgment. 3. Cryptococcal meningitis and cryptococcosis at other sites: The usual dose of this drug is 400 mg once on the first day, followed by 200-400 mg once daily starting the next day. The duration of treatment is determined by clinical and mycological response, but treatment should generally continue for at least 6 ~ 8 weeks. 4. To prevent recurrence of cryptococcal meningitis in patients with AIDS, administer 200 mg of this drug once daily indefinitely after the patient has completed primary treatment. 5. Prevention of fungal infections in immunocompromised patients at risk due to neutropenia caused by cytotoxic chemotherapy, radiation therapy, or bone marrow transplantation: Administer 50-400 mg of this drug once daily, according to the patient's risk of fungal infection. A dose of 400 mg once daily is recommended for patients at very high risk of systemic fungal infection, such as those with severe or prolonged neutropenia following bone marrow transplantation. In these patients, administer 400 mg starting 5-6 days before the anticipated onset of neutropenia, and continue 400 mg for 1 week after the neutrophil count has increased to 1,000 cells/mm3 or more. 6. For onychomycosis of the fingernails or toenails, administer 150 mg once weekly; continue treatment until the fingernails or toenails have regrown (until uninfected new nails have grown). Fingernails generally take 3-6 months to regrow, and toenails 6-12 months. Growth rates may vary by age and individual. In some cases, the nails may remain damaged even after successful treatment with long-term use. For cutaneous fungal infections, including athlete's foot (tinea pedis), tinea corporis, jock itch (tinea cruris), and cutaneous candidiasis: The usual dose of this drug is 50 mg once daily or 150 mg once weekly for 2-4 weeks. However, athlete's foot may require treatment for 6 weeks depending on the course of the disease. For tinea versicolor, administer 50 mg once daily for 2-4 weeks. ○ Elderly patients If renal function is normal, the usual adult dose is administered. In patients with renal impairment (creatinine clearance 50 mL/min or less), the dose should be reduced or the dosing interval extended. ○ Patients with renal impairment This drug is excreted mainly in the urine unchanged. No dose adjustment is required for a single dose; however, when multiple doses are required, administer the usual dose only on the first day, then adjust the dose as follows starting the next day. Creatinine clearance (mL/min) / Recommended dose > 50 / 100 % of the usual dose ≤50 (not on dialysis) / 50% of the usual dose Patients on hemodialysis / 100% of the usual dose after each hemodialysis session Patients receiving hemodialysis should receive 100% of the usual dose after each hemodialysis session. On days when dialysis is not performed, administer a reduced dose according to creatinine clearance.

This drug should not be administered to certain patients. Firstly, patients who have had allergic reactions to this medication or azole drugs, pregnant women or women who may become pregnant, and nursing mothers should not use this medication. Furthermore, patients taking certain medications that may interact with this drug should also avoid it, as serious side effects could occur. This medication contains lactose, hence patients with lactose intolerance or related genetic disorders should refrain from taking it. This drug should be used cautiously in patients who have kidney or liver dysfunction, cardiac diseases, or electrolyte imbalances that pose a risk of arrhythmias. Additionally, patients with a history of drug allergies should be cautious. This medication inhibits certain enzymes (CYP2C9, CYP2C19, CYP3A4), so patients must be closely monitored when taking other drugs metabolized by these enzymes. Generally, this medication is safe, but in rare cases, it can affect blood, liver, and kidney function, and may present skin rashes or allergic reactions. Symptoms such as headaches, dizziness, dyspepsia, and vomiting may occur, necessitating consultation with a physician if abnormal symptoms arise. During pregnancy, this medicine should not be used, and women of childbearing age must employ effective contraception during and for one month post-treatment. Nursing mothers are also advised not to take this medication. Regular blood, liver, kidney function tests, and electrolyte tests should be performed during treatment, especially for patients with severe disease. This drug interacts with numerous other medications; thus, all medications being taken must be disclosed to healthcare providers, and careful monitoring is necessary when used in combination. When driving or operating machinery, caution is required as this medication may cause dizziness or seizures. In cases of overdose, hallucinations or abnormal behaviors may occur, requiring immediate medical evaluation and treatment. This drug is primarily excreted through urine; therefore, adequate fluid intake and, if necessary, dialysis are advisable to facilitate elimination.

Agranulocytosis, leukopenia, neutropenia, thrombocytopenia, anaphylaxis, angioedema, hypertriglyceridemia, hypercholesterolemia, hypokalemia, insomnia, drowsiness, headache, seizures, dizziness, paresthesia, dysgeusia, tremor, vertigo, Torsade de pointes, QT prolongation, abdominal pain, diarrhea, nausea, vomiting, dyspepsia, bloating, dry mouth, increased ALT, increased AST, increased alkaline phosphatase in the blood, cholestasis, jaundice, increased bilirubin, hepatotoxicity, liver failure, hepatic necrosis, hepatitis, hepatocellular damage, rash, itching, urticaria, increased sweating, drug rash, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, facial edema, hair loss, drug reaction with eosinophilia and systemic symptoms, myalgia, fatigue, lethargy, asthenia, fever, adrenal insufficiency, hallucinations, behavioral disturbance

This medication should be stored in a sealed container as it may be sensitive to air and moisture. It is advisable to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature. Proper storage helps to maintain the drug's effectiveness over time.

Appearance

Pink rectangular tablets

Package unit

30 tablets/bottle